RNAM Avidity Biosciences Inc
Healthcare$72.86+0.05%ClosedMarket Cap: $11.26B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
6.44
P/S
600.12
EV/EBITDA
-14.79
DCF Value
$-4.03
FCF Yield
-5.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.9%
Operating Margin
-3977.3%
Net Margin
-3650.4%
ROE
-44.9%
ROA
-35.0%
ROIC
-42.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $860.0K | -74.0% | $-254.5M | $-237.1M | $— | — |
| FY null | $18.8M | 77.9% | $-745.9M | $-684.6M | $— | — |
| Q3 null | $12.5M | 91.5% | $-188.8M | $-174.4M | $— | — |
| Q2 null | $3.8M | 78.8% | $-171.1M | $-157.3M | $— | — |
| Q1 null | $1.6M | 50.1% | $-131.5M | $-115.8M | $— | — |
| Q4 null | $3.0M | 75.2% | $-121.0M | $-102.3M | $— | — |
| FY null | $10.9M | 74.5% | $-378.9M | $-322.3M | $— | — |
| Q3 null | $2.3M | 69.6% | $-98.1M | $-80.4M | $— | — |
| Q2 null | $2.0M | 66.4% | $-82.6M | $-70.8M | $— | — |
| Q1 null | $3.5M | 81.9% | $-77.2M | $-68.9M | $— | — |
| Q4 2023 | $2.2M | 72.0% | $-66.7M | $-60.4M | $-0.79 | — |
| FY null | $9.6M | 78.0% | $-235.6M | $-212.2M | $— | — |